CD8A and melanoma: Indeed, contrary to analysis performed on bulk CD8+ T cells, melanoma patients with higher pre-treatment TCR diversity and reduced diversity post anti-PD1 treatment in CD8+ PD1+ showed longer progression free survival (46).